In today’s briefing:
- Genscript Biotech (1548.HK) 22H1 – The Outlook and the Risks Behind
Genscript Biotech (1548.HK) 22H1 – The Outlook and the Risks Behind
- Genscript’s four business segments are the horizontal and vertical extension based on gene synthesis technology. There is also synergy between Genscript and its subsidiaries, which can promote each other’s development.
- If only from the business level, GenScript is a worthy target for investment. It has the exponential growth potential in valuation and could reach a new high in the future.
- However, our biggest worry lies in the “black swans events” . We don’t know what “new surprises” GenScript will bring us in the future.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
